Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma Read more
Impact of Adding Abatacept to Antithymocyte Globulin for Acute Graft-Versus-Host Disease Prophylaxis in Matched Unrelated Donor Hematopoietic Stem Cell Transplantation Read more
Expanded Access Program (EAP) for Obecabtagene Autoleucel (obe-cel) Out-of-specification (OOS) in Adult Patients with Acute Lymphoblastic Leukemia Read more
A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator Controlled Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With First-Line Advanced Melanoma (INTerpath-012) Read more
EXPANDED ACCESS PROTOCOL (EAP) FOR SUBJECTS RECEIVING IDECABTAGENE VICLEUCEL THAT IS NONCONFORMING FOR COMMERCIAL RELEASE Read more
A First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Patients With Advanced Solid Tumors Read more
An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer Read more
A First-In-Human, Phase 1, Open-Label, Multicenter Study of ZW251, a Novel Glypican-3 Targeting Antibody-Drug Conjugate, in Participants with Advanced Solid Tumors, Including Hepatocellular Carcinoma Read more
Identification of Novel Metabolomics and MRI Based Biomarkers Predictive of Early Radiation Induced Cardiac Toxicity Following Treatment for Thoracic Malignancies Read more
